On April 21, 2022 Binhui Biopharm reported that it has closed a $47 million Series B financing to support its R&D of oncolytic virus products (Press release, Binhui Biotechnology, APR 21, 2022, View Source [SID1234612731]). The company’s oncolytic herpes simplex virus (oHSV2) technology platform has produced its first product, BS001 (OH2) injection, which has been approved in China for single and combination drug trials. In August 2021, BS001 was approved to start US trials in various solid tumors. The company also develops viral vector vaccines, recombinant protein drugs and nucleic acid drugs. The B+ round was led by Yangtze River Pharmaceutical Group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!